INCA-6 - Moligand™, 10 mM in DMSO , CAS No.3519-82-2

CAS: 3519-82-2 Cat. No.: I1494139 Formula: C₂₀H₁₂O₂ Peso molecolare: 284.31

GRADE & PURITY Moligand™, 10 mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Panoramica

INCA-6 (Triptycene-1,4-quinone) is a cell-permeable NFAT inhibitor. INCA-6 specifically blocks targeting of NFAT(P) substrate to the calcineurin (CN) phosphatase site and is an effective inhibitor of CN-NFAT signaling.

Specifications

Specifiche e purezza

Moligand™, 10 mM in DMSO

Condizioni di conservazione di stoccaggio

Store at -80°C

Spedito in

Dry ice packs + Cold packs

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Grado

Moligand™

Nomi e identificatori

• Isomeri SMILES: C1=CC=C2C3C4=CC=CC=C4C(C2=C1)C5=C3C(=O)C=CC5=O
• Peso molecolare: 284.31
• Reaxy-Rn: 2057867
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=2057867&ln=

Application Protocols

No item-specific validated protocols are listed in the Product Data. The following outlines general, field-tested procedures for small-molecule library members.

• DMSO stock preparation
  • Equilibrate vial to room temperature in a desiccator to prevent moisture condensation.
  • Add dry DMSO to prepare a 10–50 mM stock; vortex/sonicate briefly until fully dissolved.
  • Aliquot into low-bind tubes (10–50 µL) and store at −80 °C. Avoid repeated freeze–thaw cycles.
• Serial dilution for assays
  • Prepare intermediate dilutions in DMSO, then into assay buffer/media to reach final solvent ≤0.1–1% v/v.
  • Typical screening ranges (general): 0.1 nM to 100 µM (log-spaced); adjust to expected potency class.
• Biochemical assay setup (example framework)
  • Pre-incubate compound with target protein (e.g., 10–30 min) before initiating the reaction.
  • Include vehicle, positive control, and no-enzyme/background controls. Measure in technical triplicates.
• Cell-based assay notes
  • Confirm vehicle tolerance; pre-warm media; add compound to achieve uniform mixing; monitor for precipitation.
  • Include cytotoxicity counterscreens (e.g., CellTiter viability) alongside functional readouts.
• Data integrity
  • Record exact stock concentration, lot number, and thaw count. Archive raw data and plate maps.

For specialized applications (SPR/ITC/NMR or high-content imaging), adapt solvent percentages, buffer composition, and equilibration times to instrument guidance and target biology.

Biological Roles

Item-specific biological targets or mechanisms are not provided in the Product Data for INCA-6. Accordingly, the following applies as general guidance for small-molecule library members used as research probes:

• Functional role in studies (general)
  • Such compounds are commonly evaluated as putative modulators of enzymes, receptors, transporters, or protein–protein interactions. Definitive biological roles require experimental confirmation (e.g., binding assays, cellular phenotyping, genetic orthogonals).
• Use in pathway mapping
  • Dose-dependent phenotypes in cells or lysates can be integrated with transcriptomics/proteomics to infer likely pathways, subject to orthogonal validation.
• Selectivity and off-target considerations
  • Library ligands may display polypharmacology; counter-screens across related targets and basic cytotoxicity profiling are recommended early.
• Controls and benchmarking
  • Include vehicle, positive control (reference inhibitor/agonist if available), and inactive analog controls to contextualize any observed activity.
• Data hygiene
  • Check for fluorescence/absorbance interference and aggregation (use detergent controls; test in presence of 0.01–0.05% non-ionic surfactant and vary protein concentration) to rule out assay artifacts.

No clinical or therapeutic roles are implied. For any claim of mechanism or selectivity, rely on primary literature tied to a confirmed structure and your own orthogonal validation.

Buffer Applications

INCA-6 is not a buffering reagent. However, buffer composition profoundly affects small-molecule assay performance.

• Vehicle management
  • Keep DMSO (or other co-solvent) at the lowest feasible level (commonly ≤0.1–1% v/v). Match vehicle across all controls and test wells.
• Recommended buffer frameworks (select per assay)
  • Enzymatic assays: HEPES or Tris (25–50 mM), pH 7.2–7.8; include 100–150 mM NaCl if protein stability benefits; add Mg2+/Zn2+ only if required by the target.
  • Cell-based assays: Growth media with serum as appropriate; pre-warm and equilibrate CO2/pH before compound addition.
  • Biophysical assays: PBS or HEPES at ionic strength compatible with the technique (e.g., low-salt for ITC base runs); add 0.005–0.05% Tween-20 to mitigate nonspecific binding/aggregation when compatible.
• Practical preparation tips
  • Filter (0.22 µm) and degas buffers for sensitive biophysical methods (SPR/ITC); equilibrate to assay temperature.
  • Verify compound stability across the intended pH and salt range; check for precipitation after dilution from DMSO.

Note: No item-specific buffering capacity or pKa information is available in the Product Data; tailor buffer to the biological system and confirm that buffer constituents do not react with or sequester the compound.

Green Alternatives

Because INCA-6 is primarily used as a research ligand rather than a reaction solvent or bulk reagent, “green alternatives” pertain mainly to solvent choices for dissolution and assay preparation.

• Minimize DMSO/DMF usage
  • While DMSO is generally acceptable at ≤0.1–1% in bioassays, aim for the lowest feasible final vehicle percentage and consider ethanol or buffered aqueous systems when solubility allows.
• Prefer aqueous media when possible
  • Incrementally titrate co-solvent content, use gentle warming or pH adjustment within biologically tolerated ranges to reduce organic solvent load.
• Microdosing and high-concentration stocks
  • Prepare higher-concentration DMSO stocks (as solubility allows) to reduce the delivered solvent volume per well in HTS/CRS formats.

Illustrative comparison (general; not item-specific)

• DMSO: high solvency, low volatility; modest EHS profile; widely accepted in screening.
• Ethanol: renewable feedstock; more volatile; biological tolerance often ≤1–2%.
• Aqueous buffer with minimal surfactant: lowest environmental burden; requires intrinsic solubility.

Operational tips

• Use sealed, low-dead-volume plates/vials to minimize evaporation and waste.
• Plan batch-wise assay setups to fully use thawed aliquots, limiting solvent/compound discards.

Note: Selection must balance compound solubility/stability, assay performance, and EHS considerations. Validate any solvent change against your biological readout.

Pharmaceutical Uses

This product is supplied strictly for research use only (per Product Data) and is not intended for human or animal therapeutic, diagnostic, or clinical applications. No pharmacopeial status is indicated.

Relevant non-clinical/formulation contexts (general):

• Early discovery screening and hit validation in biochemical or cellular assays.
• Pre-formulation feasibility experiments to assess solubility, stability (pH/oxidation/light), and vehicle tolerance for in vitro studies.
• Exploratory biopharmaceutics measurements (e.g., in vitro permeability, protein binding) using research-grade material.

What is not covered or implied:

• No claims are made regarding therapeutic efficacy, safety, or suitability for clinical trials.
• No GMP documentation, stability studies per ICH, or compendial testing is provided unless explicitly stated on the CoA.

Best practices for research formulation work:

• Use fresh, accurately quantified DMSO stocks; record vehicle % in all reports.
• For in vivo exploratory work (if institutionally permitted), independently verify identity/purity and consult institutional oversight; however, this product is labeled for research use only and not for use in diagnostic or therapeutic procedures.

Physical Properties

Item-specific physicochemical parameters have not been provided for this catalog entry. Where applicable, confirm with the CoA/Spec Sheet for your lot.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point (literature or computed): Not available in Product Data; verify via CoA or internal DSC/MP.
• Boiling point (literature): Not applicable/unknown for solid bioactive small molecules; typically not used.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• LogP/logD, pKa (literature/computed): Not available in Product Data. If needed for modeling, compute from a verified structure or measure by shake-flask or potentiometric titration.
• Solubility guide (general practice)
  • Primary solvent: anhydrous DMSO (prepare a concentrated stock solution, e.g., 10–50 mM), then dilute into assay buffer to ≤0.1–1% v/v DMSO final.
  • Secondary solvents for exploration: DMF, ethanol, methanol, or aqueous buffers with co-solvent/surfactant (e.g., 0.5–1% Tween-80) as compatible with your biology.
  • If precipitation is observed upon dilution: warm gently (≤37 °C), vortex, and consider stepwise dilution or add co-solvent.
• Spectral properties
  • UV/Vis cutoff or ε: Not specified for this item; refer to CoA/Spec Sheet.
  • NMR/MS reference: Not specified for this item; refer to CoA/Spec Sheet.

Note: Treat all non-specified values as unknown until confirmed experimentally or from the CoA/SDS.

Quality and Grades

• Supplied grade: Moligand™ (from Product Data)
  • Moligand designates inclusion in a small-molecule/compound library suitable for discovery biology, screening, and mechanistic studies. While intended for research assays, Moligand grade does not imply suitability for clinical, diagnostic, or GMP manufacturing use.
• Purity/assay
  • Specific purity, residual solvent content, or chromatographic specifications are not listed here. Not specified for this item; refer to CoA/Spec Sheet.
• Impurity and identity control (general expectations for library compounds)
  • Typical QC may include LC–MS identity confirmation and area% purity by HPLC/UPLC with multi-wavelength detection; orthogonal NMR may be provided upon request or performed in-house by the user for critical applications.
• Stabilizers/additives
  • Any stabilizers or counterions are not specified. Not specified for this item; refer to CoA/Spec Sheet.
• What this means for your work
  • For quantitative biology (e.g., potency, SAR, biophysics), verify lot-specific purity and identity from the CoA and, if necessary, perform supplemental QC (e.g., quantitative NMR, ion chromatography for counterions/salts).
  • For LC-based analytics or HTS, pre-filter DMSO stocks (0.2 µm PTFE) if particulate forms on thaw/dilution, and record exact stock concentration by gravimetry or UV if the extinction coefficient is known.

Reaction and Applications

This item is positioned as a small-molecule ligand from a screening library rather than a synthetic reagent. Consequently, it is not typically selected for stoichiometric transformations or as a catalyst/auxiliary in organic synthesis.

Applicable uses in research workflows (general):

• Chemical biology
  • Probe candidate for pathway interrogation, phenotypic screening, and preliminary mechanism-of-action hypotheses when target association data are available from literature or follow-up studies.
• Biophysics and binding assessment
  • Evaluate target engagement via DSF/thermal shift (nanoDSF), SPR, ITC, MST, or NMR (WaterLOGSY/STD-NMR) using DMSO stocks and matched vehicle controls.
• Cell-based pharmacology
  • Perform dose–response viability or reporter assays to establish approximate potency ranges; confirm with orthogonal readouts to assess compound liability (e.g., fluorescence interference).
• ADME-in-miniature
  • Early solubility, permeability (PAMPA/MDCK), and microsomal stability can be profiled from the same DMSO stock to inform follow-up chemistry.

Not typically applicable: cross-coupling, reductions/oxidations, or named reactions, unless you are derivatizing the scaffold for SAR. If synthetic derivatization is intended, acquire the verified structure and consult primary literature or perform small-scale feasibility screens to define conditions compatible with the scaffold’s functional groups.

Reaction Conditions

No reaction or transformation conditions are specified for this item. As a library ligand intended for biological testing, INCA-6 is ordinarily not employed as a reagent under synthetic reaction conditions.

If you plan to modify the scaffold (general best practice):

• Solvents: Dry polar aprotic media (e.g., DMF/DMAc, DMSO, MeCN) or alcoholic solvents as dictated by the functional groups; use inert atmosphere for air/moisture-sensitive steps.
• Temperatures: Prefer ambient to ≤80 °C unless the scaffold is demonstrably stable at higher temperatures.
• Catalysts: If cross-coupling is envisioned (e.g., Suzuki, Buchwald–Hartwig), select catalysts/ligands appropriate for the aryl/vinyl system and avoid conditions that could degrade heteroaromatics.
• Times/yields: Optimize on milligram scale first; monitor by LC–MS/UPLC. Typical small-molecule derivatizations run 0.5–16 h depending on reactivity.
• Workup/purification: Quench to benign pH; extract with compatible solvents; purify by flash chromatography or prep HPLC as needed; verify identity/purity with orthogonal methods.

For purely biological applications, this section is not typically applicable; focus instead on solvent selection, assay setup, and storage guidance.

Safety and Handling

Safety information specific to INCA-6 is not included in the Product Data. Always consult the SDS for authoritative guidance.

• GHS classification, signal word, pictograms, H-statements: Not specified for this item; refer to SDS.
• General laboratory precautions (good practice)
  • Wear appropriate PPE: lab coat, safety glasses, and suitable chemical-resistant gloves (e.g., nitrile). Work in a certified chemical fume hood when handling powders or concentrated solutions.
  • Avoid inhalation of dust/aerosols. Prevent skin/eye contact. Wash thoroughly after handling.
• Handling considerations for small-molecule libraries
  • Minimize freeze–thaw cycles of DMSO stocks (aliquot upon first dissolution).
  • Use anhydrous solvents where solubility requires; recap vials promptly to limit moisture uptake and oxidation.
  • If compound is light- or air-sensitive (not specified), protect from light and handle under inert atmosphere as feasible.
• Incompatibilities (general)
  • Avoid strong oxidizers, strong acids/bases, and reactive acylating/alkylating agents unless compatibility is known.
• First aid (summary; consult SDS)
  • Skin/eye contact: Rinse with water for at least 15 minutes; remove contaminated clothing; seek medical attention if irritation persists.
  • Inhalation: Move to fresh air; seek medical advice if symptoms occur.
  • Ingestion: Rinse mouth; do not induce vomiting; obtain medical attention.
• Spill/leak response
  • Contain and collect with inert absorbent; avoid raising dust; dispose according to institutional and local regulations.

Solvent Selection

With no structure-specific solubility provided, select solvents using a tiered screening approach appropriate for bioactive small molecules.

• Primary stock solvent
  • Anhydrous DMSO is the first choice for most library compounds due to broad solvency, low volatility, and assay compatibility up to about 0.1–1% v/v in aqueous buffers.
• Secondary/alternative solvents
  • DMF (excellent solvency; ensure compatibility with biology and minimize final %).
  • Ethanol or methanol (useful for less lipophilic compounds; may enable aqueous cosolvency).
  • Aqueous buffers with co-solvent or non-ionic surfactant (e.g., 0.01–0.1% polysorbate 80) when tolerated by the assay.
• Practical guidance
  • Start with 10–50 mM DMSO stocks; verify clarity and absence of precipitate after dilution into assay buffer at planned final concentrations.
  • Warm gently (≤37 °C) and sonicate briefly to aid dissolution if needed; avoid extended heating.
  • For acid/base-sensitive targets, evaluate pH effect on solubility and stability (pH 6.5–7.5 typically preferred for cell assays).
• Comparison snapshot (general)
  • DMSO: highest solvency; hygroscopic; low volatility; compatible at low % in most assays.
  • EtOH/MeOH: volatile; lower solvency for hydrophobes; can affect cells at ≥1–2%.
  • DMF: strong solvency; potential biological interference; limit final % to the lowest feasible.

Note: Confirm final vehicle tolerance in your specific biological system and document the vehicle % in reports for reproducibility.

Storage and Reconstitution

• Storage conditions (from Product Data)
  • Store at −80 °C.
  • Shipped on dry ice packs + cold packs to maintain low temperature during transit.
• Stability notes (general for small molecules)
  • Keep material dry and protected from ambient moisture; allow vials to equilibrate to room temperature in a desiccator before opening to prevent condensation.
  • If light sensitivity is suspected, protect from light (amber vials, foil wrap).
• Reconstitution guidance
  • Preferred solvent: anhydrous DMSO unless otherwise indicated on the CoA.
  • Prepare concentrated stocks (e.g., 10–50 mM), vortex/sonicate to dissolve completely.
  • Immediately aliquot into single-use portions (low-bind tubes) to avoid repeated freeze–thaw cycles. Label aliquots with compound ID, concentration, solvent, date, and lot number.
• Working solution preparation
  • Dilute into assay buffer/media to the desired final concentration ensuring vehicle (e.g., DMSO) does not exceed assay tolerance (commonly ≤0.1–1% v/v).
  • Inspect for precipitation or turbidity; if observed, gently warm (≤37 °C) and mix; if unresolved, adjust dilution strategy or co-solvent fraction.
• Shelf life
  • Item-specific shelf-life and solution stability: Not specified for this item; refer to CoA/Spec Sheet. As a general precaution, minimize time at room temperature and avoid >3–4 freeze–thaw events.

Always defer to the lot-specific CoA and SDS for definitive storage and handling instructions.

Structure and Identity

Overview: INCA-6 (SKU I1494139) is supplied as part of Aladdin’s Moligand small-molecule/compound library for research screening and discovery workflows.

• Product identifiers
  • SKU: I1494139
  • Product name: INCA-6
  • CAS: 3519-82-2
  • PubChem CID: 230748
  • Category: Small molecules and compound libraries (小分子和化合物库)
• Structure-related fields from Product Data
  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
  • InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• Structural description (general)
  • Specific structural features (ring systems, heteroatoms, stereocenters) are not provided in the current listing. For definitive identity confirmation (e.g., 1H/13C NMR, HRMS, LC–MS retention), consult the Certificate of Analysis accompanying the lot delivered.
• Identity verification recommendations (general best practice)
  • Cross-check CAS and CID against authoritative databases (PubChem, CAS Registry) prior to use in regulated or GLP-adjacent studies.
  • If structural information is critical to your study design (e.g., docking, SAR, chemoproteomics), request the latest CoA/Spec Sheet and, if needed, perform incoming QC (LC–MS purity/identity and orthogonal NMR).

Synthetic Utility

INCA-6 is offered as a discrete small-molecule library member rather than a general synthetic building block or reagent. In typical workflows, it is used as-received in biological assays rather than transformed chemically.

If derivatization or SAR expansion is planned (general guidance):

• Obtain the verified structure (SMILES/InChI) and functional group map from the CoA or primary literature before planning synthesis.
• Identify vectors for substitution that preserve putative pharmacophores; design a limited matrix of analogs to probe potency/solubility/metabolic liability.
• Choose transformations compatible with the scaffold (e.g., avoid strong acids/bases, oxidants, or high-temperature conditions if the core is labile). Protect sensitive heterocycles or anilides during cross-couplings or acylations as needed.
• Plan robust, orthogonal analytics (UPLC, 1H/13C NMR, HRMS) for rapid cycle times and purity confirmation (>95% typical target for bioassays; set your own threshold).

For most users focusing on biology, no synthetic utility is required; instead prioritize aliquoting, solubility optimization, and rigorous assay controls to generate reproducible data.

Target Specificity

No target, pathway, or binding specificity information is provided in the Product Data for INCA-6. Consequently, no claims are made here regarding molecular targets, selectivity windows, or species reactivity.

Recommendations for users establishing specificity (general):

• Perform primary activity screens across the hypothesized target class and include close homologs to gauge selectivity.
• Use orthogonal binding/functional assays (e.g., enzymatic IC50 vs. SPR/ITC Kd) to confirm direct engagement.
• Evaluate potential assay interference (fluorescence quenching, aggregation, redox cycling) with control experiments (detergent, protein titration, redox buffers).
• If proteomic methods are available, consider target deconvolution (e.g., DARTS, CETSA/TPP, photoaffinity where permissible with analogs) after confirming phenotypic activity.

Please consult the CoA/Spec Sheet and primary literature for any lot- or scaffold-specific target information before making experimental claims.